We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| LumiraDx Ltd | NASDAQ:LMDX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.016 | 0.014 | 0.0146 | 0 | 01:00:00 |
From May 2023 to May 2024
By Sabela Ojea
LumiraDx said Friday that it submitted a dual U.S. Food and Drug Administration medical devices application for the clearance of its Covid-19 ultra test.
The diagnostic technology company said its 510(k) dual submission aims to receive approval for the commercial distribution at point of care of the LumiraDx platform, which enables lab-comparable performance across a broad menu of diagnostic assays, in conjunction with its Covid-19 test and Covid-19 Ag Quality control swab kit.
The company had received several emergency use authorizations for its Covid-19 tests during the pandemic.
At 14:50 E.T., shares rose 2.7%, to 44 cents.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
June 30, 2023 15:11 ET (19:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year LumiraDx Chart |
1 Month LumiraDx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
